Adjuvant radiation therapy alone is associated with improved overall survival compared to hormonal therapy alone in older women with estrogen receptor positive early stage breast cancer
Open Access
- 17 September 2020
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 9 (22) , 8345-8354
Abstract
Background: Breast conserving surgery (BCS) and adjuvant hormonal therapy (HT) without radiation therapy (RT) is an acceptable approach for older women with early stage, estrogen receptor (ER) positive breast cancer. Toxicity and compliance remain issues with HT. Adjuvant RT alone may have better compliance, but its efficacy in the absence of HT is unclear. We aim to assess patterns of adjuvant therapy and survival outcomes among older women with early stage, ER positive (ER+) breast cancer.Methods: The National Cancer Data Base (NCDB) was used to identify 130,194 women age ≥65 years with invasive ER+, node negative breast cancer diagnosed between 2004 and 2015. All patients underwent BCS. Kaplan‐Meier survival curves were used to examine overall survival (OS). The association between adjuvant therapy and OS was assessed in multivariable Cox proportional hazards regression models.Results: Unadjusted 5/10‐year OS rates were 90.0%/64.3% for HT and RT, 84.2%/54.9% for RT alone, 78.7%/44.5% for HT alone, and 71.6%/38.0% for no treatment; padj: 0.84) and 10 (HRadj: 0.87) years.Conclusions: Older women with early stage ER+ breast cancer who undergo BCS and receive both HT and RT have the best survival, while RT as single‐modality therapy had higher rates of OS at 5 and 10 years compared to HT alone.Keywords
This publication has 18 references indexed in Scilit:
- Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guidelinePractical Radiation Oncology, 2018
- Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast CancerJAMA Oncology, 2018
- Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast CancerJournal of Clinical Oncology, 2015
- Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trialThe Lancet Oncology, 2015
- Frailty and Adherence to Adjuvant Hormonal Therapy in Older Women With Breast Cancer: CALGB Protocol 369901Journal of Clinical Oncology, 2014
- Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343Journal of Clinical Oncology, 2013
- Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic reviewBreast Cancer Research and Treatment, 2012
- Lumpectomy Plus Tamoxifen or Anastrozole With or Without Whole Breast Irradiation in Women With Favorable Early Breast CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Tamoxifen with or without Breast Irradiation in Women 50 Years of Age or Older with Early Breast CancerNew England Journal of Medicine, 2004
- Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast CancerNew England Journal of Medicine, 2004